Gwo Xi Stem Cell Applied Technology Co. , Ltd
TWO: 6704.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chuan-Feng Chiu
- Employees
- 49
- Headquarters
- Zhubei, Taiwan
- IPO year
- 2023
- Market cap
- NT$2.1B
- Website
- https://www.gwoxi.com.tw
Loading 6704…
Loading profile data…Frequently asked questions about 6704
What does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) do?
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company's products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived ste...
Where does 6704.TWO trade?
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) trades on the Taipei Exchange.
What sector is 6704.TWO in?
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gwo Xi Stem Cell Applied Technology Co. , Ltd?
Chuan-Feng Chiu is the chief executive officer of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO).
Where is Gwo Xi Stem Cell Applied Technology Co. , Ltd headquartered?
Gwo Xi Stem Cell Applied Technology Co. , Ltd is headquartered in Taiwan.
Does 6704.TWO pay a dividend?
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6704.TWO go public?
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) completed its initial public offering in 2023.